Please contact Matt Crocker at crockerm@ohsu.edu or 503-418-9389 with questions.
Breast Cancer

**Surgical Therapy**

- **Pre-Op Therapy**
  - IRB# 6256
  - ISPY2
  - Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2

- **Surgical Therapy**
  - No Trial Currently Available

- **Adjuvant Therapy**
  - IRB# 17461
  - SI418
  - A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy

- **1st Line MBC Therapy**
  - IRB# 18504
  - Phase 2 Olaparib and Durvalumab in Patients with Metastatic Triple Negative Breast Cancer

- **2nd or 3rd Line MBC Therapy**
  - IRB# 19200
  - DS-8201a vs. Physician’s Choice for HER2-low Unresectable/Metastatic BC

- **Heavily Pre-Treated Therapy**
  - IRB# 15588
  - Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART)

**TRIPLE NEGATIVE (EP/PR NEGATIVE HER2 NEGATIVE)**

**CROSS-DISEASE TRIALS:**

- IRB# TBD
  - EAY131 (MATCH)

- IRB# 18084
  - S1609 DART

**http://www.ohsu.edu/research/rda/so/knight.php**

07 Mar 2020